Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
Protein L is known as a “superantigen” because it can bind antibodies in unusual ways
The ‘265 Patent is based on Enanta’s July 2020 patent application describing coronavirus protease inhibitors invented by Enanta scientists
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
Vivo Bio Tech will have end-to-end responsibility for conducting the full spectrum of pre-clinical safety and regulatory studies
Subscribe To Our Newsletter & Stay Updated
